Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia (Q36623056)

15 August 2017

1 reference

title

Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia (English)

1 reference

15 August 2017

0 references

John R Burnett

1

1 reference

15 August 2017

Murray W Huff

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

15

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1337-1351

1 reference

Genetic regulation of cholesterol absorption and plasma plant sterol levels: commonalities and differences

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Molecular mechanisms of cholesterol absorption and transport in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Sterol absorption by the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Cholesterol and plant sterol absorption: recent insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Plant sterol and stanol margarines and health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Increases in dietary cholesterol are associated with modest increases in both LDL and HDL cholesterol in healthy young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

The discovery of ezetimibe: a view from outside the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Beta-lactam cholesterol absorption inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Scavenger receptor class B type I reduces cholesterol absorption in cultured enterocyte CaCo-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Accelerated lipid absorption in mice overexpressing intestinal SR-BI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Calreticulin facilitates the cell surface expression of ABCG5/G8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Common sequence variations in ABCG8 are related to plant sterol metabolism in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Dietary cholesterol and plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

The mechanism of ABCG5/ABCG8 in biliary cholesterol secretion in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Dietary cholesterol and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Dietary cholesterol and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary heart disease: the Seven Countries Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Dietary fat intake and the risk of coronary heart disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Dietary fat and risk of coronary heart disease in men: cohort follow up study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Atherogenesis: a postprandial phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Acyl-coenzyme A:cholesterol acyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

The structure of acyl coenzyme A-cholesterol acyltransferase and its potential relevance to atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: impact on hepatic cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Effect of ACAT inhibition on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Intestinal bile acid transport: biology, physiology, and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

New insights into bile acid transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

The role of orphan nuclear receptors in the regulation of cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 alpha-hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Colesevelam: potential uses for the newest bile resin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Ezetimibe and statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Ezetimibe and other azetidinone cholesterol absorption inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Therapeutic potential of plant sterols and stanols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Phytosterols and cholesterol metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Dietary vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3-Leiden transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Cholesterol-lowering effects of plant sterol esters and non-esterified stanols in margarine, butter and low-fat foods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Phytosterols in human nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Effects of a novel hydrophilic phytostanol analog on plasma lipid concentrations in gerbils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Influence of phytostanol phosphoryl ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

The enzymatic and non-enzymatic roles of protein-disulfide isomerase in apolipoprotein B secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Current biology of MTP: implications for selective inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Liver dysfunction and steatosis in familial hypobetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Lipid disorders and mutations in the APOB gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

Localization and role of NPC1L1 in cholesterol absorption in human intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1337

10.1517/13543784.15.11.1337

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference